Talon Therapeutics Inc (fka TLON)

[operating_line]

It does not smell right.

I do not use etrade and already changed broker from when I bought TLON shares. I was not able to move the CVRs from the original place since they are non-tradeable securities. They needed to remain and I have no way to see them online now. I have not been in contact to check on them recently.

I do not understand the reason you provided for their removal from the brokerage account:
"Because DTCC does Not have Transferring Agents of TLON "

DTCC are a brokerage based holder of all street stock. It seems they may not be aware that Equiniti are the new rights agent as the successor. I think the next step is to show e-trade the link of the acquisition and the SEC terms below and ask that they discuss that with DTCC, who can confirm the details. Only the brokerage communicates with DTCC. Hopefully this may lead to the CVRs restored to the original brokerage account since the CVRs are in book entry only, cannot be issued in physical form. If that is not successful, the other route is to contact the pharma companies that are currently involved with Marqibo to request assistance on restoring the CVRs (contact Acrotech and/or CASI Pharmaceuticals).

1. Equiniti is the successor rights agent. Corporate Stock Transfer, Inc. who handled the acquisition of Talon Therapeutics by Spectrum Pharmaceuticals was acquired by Equiniti Trust Company.

https://equiniti.com/us/shareowner-online/acquisition-of-corporate-stock-transfer/

2. The terms of the CVRs are explicit per the SEC filing.

"Termination. Any liability of Parent and its successors and or assigns with respect to, and the obligation to pay, any Milestone Amounts, other than the Regulatory Milestone, or any directly related payments pursuant to this Agreement shall be terminated and of no force or effect upon the date that is 20 years after the date of this Agreement. Any liability of Parent and its successors and or assigns with respect to, and the obligation to pay, the Regulatory Milestone Amount or any directly related payments pursuant to this Agreement, shall be terminated and of no force or effect upon the expiration of the Menadione Patent Rights. This Agreement shall otherwise be terminated and of no force or effect and the parties hereto shall have no liability hereunder upon the later to occur of: (i) the date that is 20 years after the date of this Agreement; or (ii) the expiration of the Menadione Patent Rights. "

https://www.sec.gov/Archives/edgar/data/831547/000119312513295701/d568990dex23.htm

The terms of the original CVRs are here:
https://www.sec.gov/Archives/edgar/data/831547/000119312513445708/R21.htm